trabectedin

Ligand id: 2774

Name: trabectedin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 7
Hydrogen bond donors 4
Rotatable bonds 4
Topological polar surface area 194.02
Molecular weight 761.26
XLogP 1.69
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Used in the treatment of soft tissue sarcoma and ovarian cancer. In October 2015, the US FDA approved trabectedin for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have already received an anthracycline-containing chemotherapy (e.g. doxorubicin, gemcitabine, docetaxel or ifosfamide).
Mechanism Of Action and Pharmacodynamic Effects
Interrupts the cell cycle and nucleotide excision repair process in cancer cells. For a complete overview of the mechanism of action of trabectedin, see the DrugBank link on the Summary tab of this ligand page and the review by D'Incalci and Galmarini (2010) [1]. Due to the complex and varied nature of nucleic acids we do not include DNA or RNA as targets on this database.
External links